keyword
MENU ▼
Read by QxMD icon Read
search

American society of hematology

keyword
https://www.readbyqxmd.com/read/28102896/impact-of-pre-transplant-depression-on-outcomes-of-allogeneic-and-autologous-hematopoietic-stem-cell-transplantation
#1
Areej El-Jawahri, Yi-Bin Chen, Ruta Brazauskas, Naya He, Stephanie J Lee, Jennifer M Knight, Navneet Majhail, David Buchbinder, Raquel M Schears, Baldeep M Wirk, William A Wood, Ibrahim Ahmed, Mahmoud Aljurf, Jeff Szer, Sara M Beattie, Minoo Battiwalla, Christopher Dandoy, Miguel-Angel Diaz, Anita D'Souza, Cesar O Freytes, James Gajewski, Usama Gergis, Shahrukh K Hashmi, Ann Jakubowski, Rammurti T Kamble, Tamila Kindwall-Keller, Hilard M Lazarus, Adriana K Malone, David I Marks, Kenneth Meehan, Bipin N Savani, Richard F Olsson, David Rizzieri, Amir Steinberg, Dawn Speckhart, David Szwajcer, Helene Schoemans, Sachiko Seo, Celalettin Ustun, Yoshiko Atsuta, Jignesh Dalal, Carmem Sales-Bonfim, Nandita Khera, Theresa Hahn, Wael Saber
BACKGROUND: To evaluate the impact of depression before autologous and allogeneic hematopoietic cell transplantation (HCT) on clinical outcomes posttransplantation. METHODS: We analyzed data from the Center for International Blood and Marrow Transplant Research to compare outcomes after autologous (n = 3786) or allogeneic (n = 7433) HCT for adult patients with hematologic malignancies with an existing diagnosis of pre-HCT depression requiring treatment versus those without pre-HCT depression...
January 19, 2017: Cancer
https://www.readbyqxmd.com/read/28096036/a-guide-to-the-anti-innovation-pharmaphobia-narrative-for-the-aspiring-innovator
#2
Thomas P Stossel
Thomas P. Stossel is an American Cancer Society Professor of Medicine Emeritus at Harvard Medical School, Honorary Physician in the Hematology Division of Brigham & Women's Hospital, founding scientist of BioAegis Therapeutics, Visiting Scholar of The American Enterprise Institute and cofounder of Options for Children in Zambia.
February 2017: Surgery
https://www.readbyqxmd.com/read/28067888/revisiting-nutritional-support-for-allogeneic-hematologic-stem-cell-transplantation-a-systematic-review
#3
REVIEW
A Baumgartner, A Bargetzi, N Zueger, M Bargetzi, M Medinger, L Bounoure, F Gomes, Z Stanga, B Mueller, P Schuetz
In 2009, the American Society of Parenteral and Enteral Nutrition and its European counterpart (Euopean Society for Parenteral and Enteral Nutrition) published guidelines regarding nutritional support of patients with hematologic stem cell transplantation. Our aim was to do an up-to-date literature review regarding benefit of nutritional interventions and treatment recommendations. We searched MEDLINE, EMBASE and Cochrane Library for interventional and observational clinical studies. We extracted data based on a predefined case report form and assessed bias...
January 9, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28067033/2016-updated-american-society-of-clinical-oncology-oncology-nursing-society-chemotherapy-administration-safety-standards-including-standards-for-pediatric-oncology
#4
Michael Neuss, Terry Gilmore, Kristin Belderson, Amy Billett, Tara Conti-Kalchik, Brittany Harvet, Carolyn Hendricks, Kristine LeFebvre, Pamela Mangu, Kristen McNiff, MiKaela Olsen, Lisa Schulmeister, Anne Von Gehr, Martha Polovich
Purpose: To update the American Society of Clinical Oncology (ASCO)/Oncology Nursing Society (ONS) Chemotherapy Administration Safety Standards and to highlight standards for pediatric oncology. Methods: The ASCO/ONS Chemotherapy Administration Safety Standards were first published in 2009 and updated in 2011 to include inpatient settings. A subsequent 2013 revision expanded the standards to include the safe administration and management of oral chemotherapy. A joint ASCO/ONS workshop with stakeholder participation, including that of the Association of Pediatric Hematology Oncology Nurses and American Society of Pediatric Hematology/Oncology, was held on May 12, 2015, to review the 2013 standards...
6, 2017: Oncology Nursing Forum
https://www.readbyqxmd.com/read/28056525/venetoclax
#5
Amber C King, Tim J Peterson, Troy Z Horvat, Mabel Rodriguez, Laura A Tang
OBJECTIVE: To review the pharmacology, efficacy, and safety of venetoclax for treatment of lymphoid malignancies. DATA SOURCES: A literature search was performed of PubMed and MEDLINE databases (2005 to September 2016), abstracts from the American Society of Hematology and the American Society of Clinical Oncology, and ongoing studies from clinicaltrials.gov. Searches were performed utilizing the following key terms: venetoclax, ABT-199, GDC-199, obatoclax, GX15-070, BCL-2 inhibitor, navitoclax, ABT-263, and Venclexta...
December 1, 2016: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28050052/the-hematologic-definition-of-monoclonal-gammopathy-of-undetermined-significance-in-relation-to-paraproteinemic-keratopathy-an-american-ophthalmological-society-thesis
#6
Walter Lisch, Joanna Wasielica-Poslednik, Tero Kivelä, Ursula Schlötzer-Schrehardt, Jens M Rohrbach, Walter Sekundo, Uwe Pleyer, Christina Lisch, Alexander Desuki, Heidi Rossmann, Jayne S Weiss
PURPOSE: To determine if paraproteinemic keratopathy (PPK) in the setting of monoclonal gammopathy of undetermined significance (MGUS) causes distinct patterns of corneal opacification that can be distinguished from hereditary, immunologic, or inflammatory causes. METHODS: A retrospective, interventional study of patients showed distinct bilateral opacity patterns of the cornea at the eye clinics of Hanau, Mainz, Helsinki, Marburg, and Berlin between 1993 and 2015...
August 2016: Transactions of the American Ophthalmological Society
https://www.readbyqxmd.com/read/28041582/58th-american-society-of-hematology-annual-meeting
#7
Lan-Lan Smith
No abstract text is available yet for this article.
January 2017: Lancet Haematology
https://www.readbyqxmd.com/read/27956156/58th-american-society-of-hematology-annual-meeting
#8
Lan-Lan Smith
No abstract text is available yet for this article.
January 2017: Lancet Oncology
https://www.readbyqxmd.com/read/27903157/obesity-and-other-cancers
#9
Lin Yang, Bettina F Drake, Graham A Colditz
Purpose Evidence on overweight, obesity, and an increased risk of cancer continues to accumulate and was updated in the 2016 handbook on weight control from the International Agency for Research on Cancer (IARC). The underlying primary data, together with dose-response meta-analysis and, finally, pooled analysis of individual participant data, add insight into the relation between obesity and cancer risk and prognosis. We summarize the evidence for mortality from prostate cancer, hematologic malignancies, and kidney cancer...
December 10, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27880061/the-safety-profile-of-monoclonal-antibodies-for-chronic-lymphocytic-leukemia
#10
Anna Korycka-Wołowiec, Dariusz Wołowiec, Tadeusz Robak
Monoclonal antibodies (MoAbs), non-chemotherapeutic agents targeting the antigens present on chronic lymphocytic leukemia (CLL) lymphocytes, are being implemented increasingly more often as treatment options. Areas covered: This article reviews the similarities and differences in the structure, mechanism of action, efficacy and safety profile of commercially-available MoAbs and prevents new agents potentially useful for CLL treatment. Publications in English before June 2016 were surveyed on the MEDLINE database for articles...
December 4, 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27868581/2016-updated-american-society-of-clinical-oncology-oncology-nursing-society-chemotherapy-administration-safety-standards-including-standards-for-pediatric-oncology
#11
Michael N Neuss, Terry R Gilmore, Kristin M Belderson, Amy L Billett, Tara Conti-Kalchik, Brittany E Harvey, Carolyn Hendricks, Kristine B LeFebvre, Pamela B Mangu, Kristen McNiff, MiKaela Olsen, Lisa Schulmeister, Ann Von Gehr, Martha Polovich
Purpose To update the ASCO/Oncology Nursing Society (ONS) Chemotherapy Administration Safety Standards and to highlight standards for pediatric oncology. Methods The ASCO/ONS Chemotherapy Administration Safety Standards were first published in 2009 and updated in 2011 to include inpatient settings. A subsequent 2013 revision expanded the standards to include the safe administration and management of oral chemotherapy. A joint ASCO/ONS workshop with stakeholder participation, including that of the Association of Pediatric Hematology Oncology Nurses and American Society of Pediatric Hematology/Oncology, was held on May 12, 2015, to review the 2013 standards...
December 2016: Journal of Oncology Practice
https://www.readbyqxmd.com/read/27864218/second-primary-malignancies-in-multiple-myeloma-an-overview-and-imwg-consensus
#12
REVIEW
P Musto, K C Anderson, M Attal, P G Richardson, A Badros, J Hou, R Comenzo, J Du, B G M Durie, J San Miguel, H Einsele, W M Chen, L Garderet, G Pietrantuono, J Hillengass, R A Kyle, P Moreau, J J Lahuerta, O Landgren, H Ludwig, A Larocca, A Mahindra, M Cavo, A Mazumder, P L McCarthy, A Nouel, S V Rajkumar, A Reiman, E R Serra, O Sezer, E Terpos, I Turesson, S Usmani, B M Weiss, A Palumbo
BACKGROUND: Therapeutic advancements following the introduction of autologous stem cell transplantation and 'novel' agents have significantly improved clinical outcomes for patients with multiple myeloma (MM). Increased life expectancy, however, has led to renewed concerns about the long-term risk of second primary malignancies (SPMs). This review outlines the most up-to-date knowledge of possible host-, disease-, and treatment-related risk factors for the development of SPMs in patients with MM, and provides practical recommendations to assist physicians...
November 17, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27863374/magic-year-for-multiple-myeloma-therapeutics-key-takeaways-from-the-ash-2015-annual-meeting
#13
REVIEW
Kejie Zhang, Aakash Desai, Dongfeng Zeng, Tiejun Gong, Peihua Lu, Michael Wang
Despite the availability of various anticancer agents, Multiple Myeloma (MM) remains incurable in most cases, along with high relapse rate in the patients treated with these agents. The year 2015 saw major advancements in our battle against multiple myeloma. In 2015, the U.S. Food and Drug Administration (FDA) approved three new therapies for multiple myeloma, namely Ixazomib (an oral proteasome inhibitor), Daratumumab and Elotuzumab (monoclonal antibodies against CD38 and SLAMF7 respectively). The purpose of this review is to provide a detailed analysis of these aforementioned breakthrough therapies and two other newer agents, Filanesib (kinesis spindle inhibitor) and selinexor (SINE inhibitor), presented at the 2015 annual meeting of American Society of Hematology (ASH)...
November 11, 2016: Oncotarget
https://www.readbyqxmd.com/read/27859015/hla-e-allelic-genotype-correlates-with-hla-e-plasma-levels-and-predicts-early-progression-in-chronic-lymphocytic-leukemia
#14
Bettina Wagner, Fabiola da Silva Nardi, Sabine Schramm, Thomas Kraemer, Alexander A Celik, Jan Dürig, Peter A Horn, Ulrich Dührsen, Holger Nückel, Vera Rebmann
BACKGROUND: Human leukocyte antigen-E (HLA-E) is a nonclassical major histocompatibility complex class I molecule that recently came into sharper focus as a putative marker of advanced tumor stages and disease progression. In solid tumors, increased HLA-E expression as well as elevated soluble HLA-E (sHLA-E) plasma levels are associated with a poor prognosis; however, a role for HLA-E in hematologic malignancies remains to be established. METHODS: The authors analyzed HLA-E alleles and sHLA-E levels in a cohort of 110 individuals with chronic lymphocytic leukemia (CLL)...
November 2, 2016: Cancer
https://www.readbyqxmd.com/read/27843210/an-audit-of-early-complications-of-radical-cystectomy-using-clavien-dindo-classification
#15
Nitesh Patidar, Priyank Yadav, Sanjoy Kumar Sureka, Varun Mittal, Rakesh Kapoor, Anil Mandhani
INTRODUCTION: Despite the major improvements in surgical technique and perioperative care, radical cystectomy (RC) remains a major operative procedure with a significant morbidity and mortality. The present study analyzes the early complications of RC and urinary diversion using a standardized reporting system. MATERIALS AND METHODS: Modified Clavien-Dindo classification was used to retrospectively assess the peri-operative course of 212 patients who had RC with urinary diversion between October 2003 and October 2014 at a single institution...
October 2016: Indian Journal of Urology: IJU: Journal of the Urological Society of India
https://www.readbyqxmd.com/read/27784672/the-american-society-of-hematology-clinical-research-training-institute-is-associated-with-high-retention-in-academic-hematology
#16
Allison A King, Sara K Vesely, Jessica Elwood, Joe Basso, Ken Carson, Lillian Sung
No abstract text is available yet for this article.
December 22, 2016: Blood
https://www.readbyqxmd.com/read/27756146/cancer-associated-thrombosis-and-palliative-care-an-interview-with-simon-noble
#17
Simon Noble
Simon Noble speaks to Sebastian Dennis-Beron, Commissioning Editor: Simon Noble is Clinical Professor in Palliative Medicine at Cardiff University and honorary consultant at the Royal Gwent Hospital in Newport. His main research interests are in the management of venous thromboembolism in advanced cancer, quality of life effects of venous thromboembolism and their therapies, clinical decision-making in venous thromboembolism management and the patient journey. He is involved at a national level in the delivery of evidence-based thromboprophylaxis for hospitalized patients through the All Party Thrombosis Group and sits on the NICE Guideline development group for thromboprophylaxis...
January 2017: Future Oncology
https://www.readbyqxmd.com/read/27752290/reversal-of-direct-oral-anticoagulants-in-hemophilia-treatment-ash-meeting-2015
#18
Clemens Feistritzer, Stefan Schmidt
During the 57(th) annual meeting of the American Society of Hematology 2015 in Orlando, Florida, various aspects in the field of hemostaseology were presented. The Choosing Wisely® campaign pointed out the importance of the critical use of diagnostic tools to rule out pulmonary embolism and questioned the relevance of thrombophilia testing in women undergoing routine infertility evaluation. Furthermore, the approval of idarucizumab, a specific antidote for the reversal of the anticoagulant effects of the direct thrombin inhibitor dabigatran, was highlighted...
2016: Memo
https://www.readbyqxmd.com/read/27741009/reemergence-of-splenectomy-for-itp-second-line-treatment
#19
Charbel Chater, Louis Terriou, Alain Duhamel, David Launay, Jean P Chambon, François R Pruvot, Moshe Rogosnitzky, Philippe Zerbib
INTRODUCTION: Corticosteroids are still the standard first-line treatment for immune thrombocytopenic purpura (ITP). As second-line therapy, splenectomy and Rituximab are both recommended. The aim of our study was to compare the efficacy of Rituximab to splenectomy in persistent or chronic ITP patients. METHODS: Between January 1999 and March 2015, we retrospectively selected all consecutive patients who underwent an ITP second-line treatment: Rituximab or splenectomy...
November 2016: Annals of Surgery
https://www.readbyqxmd.com/read/27669661/medical-interventions-for-the-prevention-of-platinum-induced-hearing-loss-in-children-with-cancer
#20
Jorrit W van As, Henk van den Berg, Elvira C van Dalen
BACKGROUND: Platinum-based therapy, including cisplatin, carboplatin, oxaliplatin or a combination of these, is used to treat a variety of paediatric malignancies. One of the most important adverse effects is the occurrence of hearing loss or ototoxicity. In an effort to prevent this ototoxicity, different otoprotective medical interventions have been studied. This review is the second update of a previously published Cochrane review. OBJECTIVES: To assess the efficacy of medical interventions to prevent hearing loss and to determine possible effects of these interventions on anti-tumour efficacy, toxicities other than hearing loss and quality of life in children with cancer treated with platinum-based therapy...
September 27, 2016: Cochrane Database of Systematic Reviews
keyword
keyword
12147
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"